Bristol Myers Squibb Company $BMY Shares Sold by RWA Wealth Partners LLC

Key Points

• RWA Wealth Partners LLC has reduced its holdings in Bristol Myers Squibb Company by 17.7%, selling 12,225 shares and retaining 56,707 shares valued at $3.46 million.
• Institutional investors currently hold 76.41% of Bristol Myers Squibb's stock, with several firms like Wellington Management increasing their stakes significantly during the 1st quarter.
• The company reported earnings of $1.46 EPS, exceeding estimates, while also declaring a quarterly dividend of $0.62 per share, reflecting a 5.1% dividend yield.

RWA Wealth Partners LLC decreased its holdings in Bristol Myers Squibb Company (NYSE:BMY - Free Report) by 17.7% during the 1st quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 56,707 shares of the biopharmaceutical company's stock after selling 12,225 shares during the quarter. RWA Wealth Partners LLC's holdings in Bristol Myers Squibb were worth $3,459,000 as of its most recent filing with the SEC.

A number of other institutional investors and hedge funds have also recently bought and sold shares of BMY. Pinney & Scofield Inc. purchased a new position in Bristol Myers Squibb in the fourth quarter valued at about $25,000. Park Square Financial Group LLC acquired a new stake in shares of Bristol Myers Squibb in the 4th quarter valued at about $26,000. Transce3nd LLC acquired a new stake in shares of Bristol Myers Squibb in the 4th quarter valued at about $28,000. Global Wealth Strategies & Associates raised its stake in shares of Bristol Myers Squibb by 137.5% in the 1st quarter. Global Wealth Strategies & Associates now owns 475 shares of the biopharmaceutical company's stock valued at $29,000 after purchasing an additional 275 shares in the last quarter. Finally, Harel Insurance Investments & Financial Services Ltd. bought a new position in Bristol Myers Squibb during the 1st quarter worth approximately $31,000. Hedge funds and other institutional investors own 76.41% of the company's stock.

Wall Street Analyst Weigh In

Several research firms recently issued reports on BMY. Wall Street Zen lowered Bristol Myers Squibb from a "strong-buy" rating to a "buy" rating in a research report on Friday, June 6th. Citigroup reduced their price target on shares of Bristol Myers Squibb from $51.00 to $47.00 and set a "neutral" rating on the stock in a research report on Friday, August 1st. Morgan Stanley reaffirmed a "hold" rating on shares of Bristol Myers Squibb in a research report on Thursday, July 31st. Daiwa Capital Markets downgraded shares of Bristol Myers Squibb from an "outperform" rating to a "neutral" rating and set a $42.00 price objective for the company. in a research report on Tuesday, August 5th. Finally, Daiwa America downgraded shares of Bristol Myers Squibb from a "strong-buy" rating to a "hold" rating in a research report on Tuesday, August 5th. One research analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating, fifteen have given a Hold rating and one has issued a Sell rating to the company's stock. According to data from MarketBeat.com, the stock currently has a consensus rating of "Hold" and a consensus price target of $56.38.

Bristol Myers Squibb Stock Performance

Shares of Bristol Myers Squibb stock traded down $0.5880 on Friday, reaching $47.8420. 11,602,099 shares of the company were exchanged, compared to its average volume of 12,653,990. The company has a debt-to-equity ratio of 2.54, a quick ratio of 1.11 and a current ratio of 1.21. The company's 50-day moving average is $47.06 and its two-hundred day moving average is $51.12. The firm has a market cap of $97.38 billion, a price-to-earnings ratio of 19.29, a P/E/G ratio of 2.48 and a beta of 0.36. Bristol Myers Squibb Company has a 1-year low of $42.96 and a 1-year high of $63.33.

Bristol Myers Squibb (NYSE:BMY - Get Free Report) last posted its earnings results on Thursday, July 31st. The biopharmaceutical company reported $1.46 EPS for the quarter, beating the consensus estimate of $1.07 by $0.39. Bristol Myers Squibb had a return on equity of 80.04% and a net margin of 10.58%.The firm had revenue of $12.27 billion for the quarter, compared to analysts' expectations of $11.32 billion. During the same period last year, the firm earned $2.07 EPS. The firm's revenue was up .6% compared to the same quarter last year. Bristol Myers Squibb has set its FY 2025 guidance at 6.350-6.650 EPS. As a group, research analysts expect that Bristol Myers Squibb Company will post 6.74 earnings per share for the current fiscal year.

Bristol Myers Squibb Announces Dividend

The business also recently announced a quarterly dividend, which was paid on Friday, August 1st. Shareholders of record on Thursday, July 3rd were paid a dividend of $0.62 per share. The ex-dividend date of this dividend was Thursday, July 3rd. This represents a $2.48 annualized dividend and a yield of 5.2%. Bristol Myers Squibb's dividend payout ratio (DPR) is presently 100.00%.

Bristol Myers Squibb Profile

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.